News Medical on MSN4d
Gene therapy breakthrough offers hope for severe Dravet syndrome casesAAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...
Dravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of ...
The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...
Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...
A team of researchers has developed a new gene therapy for children with Dravet syndrome - a rare type of epilepsy in ...
The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...
Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million ...
Michigan Medicine researchers have developed a SCN1B gene therapy that restores brain function and survival in mice with ...
News Medical on MSN7d
Gene therapy shows promise in treating SCN1B-linked epileptic encephalopathiesDravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of symptoms in children, including seizures, intellectual disability, and even ...
Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying cause of most cases of Dravet syndrome. Stoke recently announced plans to initiate a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback